Trials / Completed
CompletedNCT02220868
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Saint Michael's Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.
Detailed description
The objective of this study is to evaluate the safety, efficacy and pharmacokinetics of sofosbuvir 400mg once daily plus ribavirin 1000-1200 mg daily in HIV-infected patients on fixed dose co-formulation emtricitabine/tenofovir/cobicistat/elvitegravir (Stribild).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir, Ribavirin, and Stribild |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-08-01
- Completion
- 2015-09-01
- First posted
- 2014-08-20
- Last updated
- 2016-08-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02220868. Inclusion in this directory is not an endorsement.